Latest Continuous Disclosure News

Scorpion Minerals has addressed recent spikes in its share price and trading volume, attributing the activity to rising global gold prices and imminent assay results from its Pharos Gold Project.

Aurum Resources Limited has had its trading suspension lifted immediately following the lodgement of its annual financial report, allowing its shares to resume trading on the ASX.

Pengana Global Private Credit Trust (ASX – PCX) has announced an $82 million entitlement and shortfall offer at $2.00 per new unit, targeting a 7% annual cash distribution yield. The Trust offers diversified exposure to global private credit funds, primarily in the US and Europe, managed by Pengana Credit with Mercer Consulting as investment consultant.

BPH Global Ltd will lift its trading suspension on 2 October 2025 following the lodgement of its annual financial report for the year ended 30 June 2025.

Platina Resources Limited has addressed ASX concerns over a sharp rise in its share price and trading volume, confirming no undisclosed information is driving the activity. The company points to recent project acquisition and heritage clearance announcements as possible catalysts.

Flynn Gold Limited’s FG1OA securities have been suspended from trading due to non-compliance with ASX listing rules, raising questions about the company’s regulatory standing.

Nelson Resources has confirmed it is in confidential negotiations for a Right to Mine contract, explaining recent unusual trading activity in its shares. The company maintains compliance with ASX disclosure rules while awaiting contract finalisation.

Myer Holdings has clarified that its FY2025 earnings aligned with market forecasts, addressing concerns following a sharp share price drop after its results announcement.

Invex Therapeutics reveals the collapse of confidential acquisition negotiations following shareholder unrest and potential board changes, clarifying recent unusual trading activity.

Southern Palladium has responded to an ASX price query denying undisclosed information behind its recent share price rise, instead pointing to positive commodity price trends and ongoing project developments.

Bio-Gene Technology Limited has addressed ASX concerns over the timing of its announcement on promising Flavocide efficacy data, confirming compliance with continuous disclosure rules after receiving final presentation materials from Purdue University.

OncoSil Medical has affirmed the materiality of the PANCOSIL Phase 1-2 trial results and detailed its compliance with ASX disclosure rules following the data presentation at CIRSE 2025.